Sartorius Stedim Biotech partners with Nanotein Technologies to develop cell therapy manufacturing
Ella Day | August 12, 2025 | News story | Mergers and Acquisitions | Corporate, Nanotein Technologies, Sartorius Stedim Biotech, cell therapy, gene therapy
Sartorius Stedim Biotech has partnered with Nanotein Technologies to expand access to immune cell activation reagents for cell therapy manufacturing. As part of the agreement, Sartorius will invest up to $3m for a minority shareholding in Nanotein and secure exclusive global distribution rights for its NanoSpark platform products.
The initial portfolio includes NanoSpark STEM-T Soluble T Cell Activator and NanoSpark GROW-NK Soluble Activator, which are designed to support the expansion of T cells and natural killer cells used in therapies such as CAR-T and NK-based cancer treatments.
Nanotein co-founder and CEO Curtis Hodge said the reagents aim to “improve cell therapy expansion by enhancing the quality and quantity of T cells and providing a feeder-free soluble activator for NK cell activation and expansion, addressing critical challenges in the manufacturing process”.
CEO of Sartorius René Fáber said the collaboration will give customers access to “some of the most promising new tools for simplifying workflows and improving immune cell manufacturing”.
The companies will also jointly develop additional products based on NanoSpark technology for the cell and gene therapy market, which continues to see rapid growth.
Nanotein, based in Berkeley, California, US, currently supplies research-use-only products, with Good Manufacturing Process-grade versions expected in late 2025 and next year.
Ella Day
12/8/25
Related Content
Major breakthrough in T-cell receptor therapy manufacturing
For the first time, researchers at the University of Chicago in the US have successfully …
ProteoNic Biosciences launches platform to enhance cell line productivity
ProteoNic Biosciences, a biotech company headquartered in Leiden, Germany has unveiled its latest technology platform, the …
Eyestem secures $10m to advance cell therapy for advanced eye disease
Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support …
